Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This phase II trial shows that combining glofitamab with R-CHOP or Pola-R-CHP is safe and effective as first-line treatment in younger patients with high-risk large B-cell lymphoma, achieving high durable response rates and manageable side
KRd and D-KRd regimens outperform VMP 9-Rd 9 in achieving deeper responses in older, fit, transplant-ineligible multiple myeloma patients, but toxicity remains a concern, particularly with quadruplet therapy.
A multimodal intervention significantly improved sexual satisfaction in hematopoietic stem-cell transplantation (HSCT) survivors compared to enhanced usual care, highlighting a promising approach for addressing sexual dysfunction in this po
The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxic
Hetrombopag demonstrates comparable efficacy and safety to thrombopoietin for platelet engraftment after allogeneic hematopoietic stem cell transplantation, offering a promising alternative in hematologic care.
A major RCT shows intermediate-dose cytarabine is noninferior to high-dose as postinduction therapy in AML, with similar survival and lower toxicity.
The combination of bexmarilimab and azacitidine shows manageable safety and promising efficacy in high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukaemia, supporting further investigation.
The AVA-PED-301 phase 3b trial demonstrates avatrombopag’s efficacy and safety as an oral thrombopoietin receptor agonist for children and adolescents with persistent or chronic immune thrombocytopenia.
Mitapivat significantly improves haemoglobin levels in adults with non-transfusion-dependent α- or β-thalassaemia, offering a promising oral therapeutic option with manageable safety profile.
Subcutaneous blinatumomab demonstrates promising efficacy and manageable safety in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, with potential to shift future administration paradigms.
Gene therapy using autologous, gene-corrected stem cells without conditioning offers sustained engraftment and reverses bone marrow failure in Fanconi anaemia-A, with a favorable safety profile.
The DREAMM-7 trial demonstrates that belantamab mafodotin with bortezomib and dexamethasone significantly improves survival in relapsed/refractory multiple myeloma, suggesting a new standard of care.
The HD21 trial shows BrECADD offers superior gonadal function recovery and higher parenthood rates, especially in men, compared with eBEACOPP for advanced-stage classic Hodgkin lymphoma, supporting BrECADD as the preferred first-line therap
A single AAV gene therapy infusion for severe hemophilia B led to sustained factor IX expression, substantial reduction in bleeding and factor use, and no late safety concerns over 13 years.
Pirtobrutinib significantly improves progression-free survival and tolerability over standard regimens in covalent BTK inhibitor-pretreated CLL/SLL, offering a promising new option for this challenging population.
A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.
Post-transplant cyclophosphamide plus cyclosporin significantly improves GVHD-free, relapse-free survival compared to standard prophylaxis in matched related donor stem cell transplantation.
Mitochondrial donation by pronuclear transfer and preimplantation genetic testing effectively reduce transmission of pathogenic mtDNA variants, offering hope for families at risk of mitochondrial diseases.
MRD-guided consolidation strategies in transplant-eligible multiple myeloma patients did not significantly improve deep remission rates over conventional approaches, questioning the clinical utility of MRD-adapted intensification.
The AGILE trial shows ivosidenib plus azacitidine more than triples median overall survival in newly diagnosed IDH1-mutated AML patients ineligible for intensive chemotherapy, with improved hematologic recovery and safety.
Open language-specific specialty feeds and department pages.